Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
06:00am, Monday, 31'st Oct 2022
DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, Novem
DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension
Theravance Biopharma plans $250 million capital return program
06:11am, Monday, 19'th Sep 2022
Theravance Biopharma Inc. TBPH, +0.20% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61% . The company will p
Theravance Biopharma to Present at Upcoming Investor Conferences
06:00am, Tuesday, 06'th Sep 2022
DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be
Theravance Biopharma, Inc.'s (TBPH) CEO Rick Winningham on Q2 2022 Results - Earnings Call Transcript
03:16am, Sunday, 07'th Aug 2022
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Of
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
01:33pm, Friday, 05'th Aug 2022
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
09:03pm, Thursday, 04'th Aug 2022
Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022
06:00am, Thursday, 28'th Jul 2022
DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, Aug
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
01:10pm, Thursday, 14'th Jul 2022
Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva?
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
05:41pm, Wednesday, 13'th Jul 2022
Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwid
Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?
09:47am, Monday, 06'th Jun 2022
Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.
Theravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2022 Results -Earnings Call Transcript
04:59am, Saturday, 07'th May 2022
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chairm
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
05:18pm, Friday, 06'th May 2022
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022
06:00am, Monday, 02'nd May 2022
DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5
